Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349791 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
A Phase 3 study of Hypoactive Sexual Desire Disorder (HSDD), sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 549
- Enrollment target
- 3
- Study locations
NCT00349791 is a Phase 3 study of Hypoactive Sexual Desire Disorder (HSDD) that has completed, run by Warner Chilcott. The registered enrollment target is 549 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT00349791, a Phase 3 study of Hypoactive Sexual Desire Disorder (HSDD), has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 549 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
Conditions Studied
Interventions
- DRUG Placebo patch
- DRUG Testosterone Transdermal System
Study Locations (3)
Illinois
- Research Facility - Chicago
Other
- Research Facility - Randwick
Quebec
- Research Facility - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 549 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00349791
The ClinicalTrials.gov registry entry for NCT00349791 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 549 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypoactive Sexual Desire Disorder (HSDD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo patch is the first listed.
NCT00349791 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Other, Quebec.
Frequently Asked Questions
What is clinical trial NCT00349791 about?
NCT00349791 is a clinical study titled "Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido". This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
What is the current status of trial NCT00349791?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 549 participants. The study started on 2002-06. Estimated completion is 2003-10.
What conditions does trial NCT00349791 study?
This clinical trial studies the following conditions: Hypoactive Sexual Desire Disorder (HSDD).
What interventions are being tested in trial NCT00349791?
The interventions under investigation include: Placebo patch (DRUG), Testosterone Transdermal System (DRUG).
Who is sponsoring clinical trial NCT00349791?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00349791 being conducted?
This trial has 3 study locations across Illinois, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.